Dr. Datasons Labs Peer Comparison

NSE: DRDATSONS | BSE: 533412

₹6.40

₹-0.30 (-4.48%)

As on 21-May-2015IST

Market cap

₹69 Cr

Revenue (TTM)

₹507 Cr

P/E Ratio

P/B Ratio

0.1

Div. Yield

0 %

Edit

	Dr. Datasons Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	69	33,911	29,031	28,149	27,692
Revenue (₹ Cr)	507	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	-6.06	414.00	288.22	387.35	-371.81
Net Margin (%)	-1.19	11.23	14.79	26.01	-3.93
RoE (%)	-1.29	8.38	29.77	25.18	-3.85
Price to Earnings	--	82.91	100.73	72.88	--
Price-To-Book	0.11	6.74	21.63	16.31	3.46

Income Statement (₹ Cr)

	Dr. Datasons Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	421.05	4,830.36	41.58	76.11	--
Total Income	428.92	4,914.64	41.73	76.68	--
Total Expenditure	364.36	3,850.53	30.00	69.99	--
EBITDA	56.69	979.83	11.59	6.12	--
Depreciation	20.44	139.92	3.35	0.80	--
EBIT	36.25	839.91	8.24	5.32	--
Interest	43.03	83.35	2.34	1.58	--
Other Income	7.87	84.28	0.14	0.56	--
Exceptional Items	-44.86	49.83	--	--	--
Profit before Tax	1.09	890.67	6.04	4.31	--
Provision for Tax	0.61	47.88	1.54	1.44	--
Profit after Tax	0.48	842.79	4.50	2.86	--

	Dr. Datasons Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	407.75	3,581.47	44.83	10.77	--
Minority Interest	--	136.17	--	--	--
Non-Current Liabilities	184.46	1,161.18	10.36	1.29	--
Current Liabilities	671.06	1,743.20	21.34	26.33	--
Total Liabilities	1,263.27	6,622.02	76.53	38.71	--

	Dr. Datasons Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	578.10	3,266.10	51.75	7.38	--
Current Assets	685.17	3,355.92	24.78	31.01	--
Total Assets	1,263.27	6,622.02	76.53	38.71	--
Total Debt*	494.78	1,906.08	21.09	12.17	--
Net Current Assets	14.11	1,612.72	3.44	4.68	--
Contingent Liabilities	0.82	267.40	4.70	--	--

	Dr. Datasons Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	134.48	1,476.29	6.29	-0.21	--
Cash Flow from Investing Activities	-225.56	-851.62	-5.46	-2.00	--
Cash from Financing Activities	-119.98	-601.32	-0.58	2.17	--
Net Cash Inflow / Outflow	-211.06	23.35	0.25	-0.04	--

	Dr. Datasons Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	5.01	18.98	13.38	29.97	--
ROE (%)	0.13	30.04	19.08	30.26	--
ROA (%)	0.04	13.36	6.16	8.85	--
EBIT Margin (%)	15.33	22.03	28.21	8.78	--
Net Margin (%)	0.11	17.15	10.78	3.74	--
Cash Profit Margin (%)	4.97	20.32	18.86	4.81	--

	Dr. Datasons Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	-19.15	-13.89	12.11	37.10	--
EBIT Growth (%)	-41.53	-49.66	21.82	30.95	--
Net Profit Growth (%)	13.29	-46.64	58.36	39.55	--
EPS Growth (%)	-50.31	-56.04	58.36	39.55	--
Book Value Growth (%)	31.82	36.37	21.09	32.03	--

	Dr. Datasons Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	276.13	6.59	0.00	0.00	--
Price / Book Value	0.33	1.55	0.00	0.00	--
Dividend Yield (%)	0.00	2.19	--	--	--
EV/EBITDA	9.71	5.73	3.52	2.02	--
Market Cap (₹ Cr)	133.43	5,016.58	0.00	0.00	--

	Dr. Datasons Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	1.21	0.54	0.47	1.13	--
Short term debt to equity ratio	0.51	0.06	0.23	0.84	--
Current Ratio	1.02	1.93	1.16	1.18	--
Quick Ratio	0.74	1.36	1.11	0.75	--
Interest Coverage	1.03	11.69	3.58	3.73	--

	Dr. Datasons Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	87.25	9.96	33.85	17.81	--
Asset Turnover	0.36	0.77	0.57	2.35	--
Receivable days	277.29	54.33	106.93	58.46	--
Inventory Days	152.58	77.43	10.49	41.85	--
Payable days	245.82	120.43	213.33	91.25	--
Cash Conversion Cycle	184.05	11.32	-95.91	9.06	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.